COVID drug cuts risk of death or hospitalisation in high-risk adults by 79%

A second drug treatment for COVID-19 has been approved by the UK medicines regulator after it was found to cut risk of hospitalisation and death in high-risk adults by 79%.

MHRA chief executive Dr June Raine
MHRA chief executive Dr June Raine (Photo: Frank Augstein/Getty Images)

The MHRA approved the monoclonal antibody treatment sotrovimab, after trials found it reduced risk of hospitalisation and death by 79% in high-risk adults with symptomatic COVID-19 infection.

The drug is the second approved in the UK to treat COVID-19 - after the MHRA approved the antiviral molnupiravir (Lagevrio) in early November.

Unlike molnupiravir, which is taken orally, sotrovimab - also known as Xevudy - is administered by intravenous infusion over 30 minutes. It has been approved for individuals aged 12 and above who weigh more than 40kg.

Regulators have said it is ‘too early’ to know whether the Omicron variant has any impact on sotrovimab’s effectiveness - and have stressed it is not intended to be used as a substitute for COVID-19 vaccination.

COVID-19 treatment

Sotrovimab has been authorised for use in people who have mild to moderate COVID-19 infection and at least one risk factor for developing severe illness, such as obesity, diabetes, heart disease or age over 55.

Clinical trials found the treatment is most effective when taken in the early stages of infection and the MHRA advises it is used ‘as soon as possible and within five days of symptom onset’. The regulator said the government and NHS would confirm in 'due course' how the treatment will be deployed.

MHRA chief executive Dr June Raine, said: ‘This is yet another therapeutic that has been shown to be effective at protecting those most vulnerable to COVID-19, and signals another significant step forward in our fight against this devastating disease.’

Chair of the Commission on Human Medicines Professor Sir Munir Pirmohamed, said: ‘When administered in the early stages of infection, sotrovimab was found to be effective at reducing the risk of hospitalisation and death in high-risk individuals with symptomatic COVID-19. [It is] another safe and effective treatment to help us in our fight against COVID-19.’

The first drug treatment against coronavirus was approved earlier this month and is recommended for use on people who contract COVID and suffer with obesity, diabetes, heart disease, or that are 60 years and older.

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register

Already registered?

Sign in

Follow Us:

Just published

GP looking tired

'Running on empty': one in four GPs warn extreme tiredness is affecting patient care

A quarter of GPs say they are regularly sleep deprived at work, while the same proportion...

Syringe extracting COVID-19 vaccine from vial

Thousands of unvaccinated GP staff face dismissal notice from February

Thousands of unvaccinated staff at GP practices could be handed their notice from...

MDU chief executive Dr Matthew Lee

Viewpoint: Tired and overworked GPs need better support

A recent survey has shown that many GPs are burnt out and exhausted. Urgent action...

Pins marking points on a map

Map: Which parts of England have the fastest-rising demand for GP appointments?

GP practices faced a massive increase in workload through 2021 as demand for appointments...

Sign pointing to entrance of COVID-19 vaccination hub

GPs partners subsidising COVID-19 vaccine campaign as bookings drop, GPs warn

GP practices running COVID-19 vaccine clinics may soon be forced to 'chuck in the...

Vaccination tracker

UK COVID-19 vaccination programme tracker

GPs across the UK are playing a leading role in the largest-ever NHS vaccination...